CSIMarket
 
Immunovant Inc   (IMVT)
Other Ticker:  
 
 
Price: $30.2700 $-0.26 -0.852%
Day's High: $30.81 Week Perf: -3.9 %
Day's Low: $ 29.99 30 Day Perf: -19.92 %
Volume (M): 1,237 52 Wk High: $ 45.58
Volume (M$): $ 37,429 52 Wk Avg: $27.99
Open: $30.33 52 Wk Low: $14.05



 Market Capitalization (Millions $) 4,375
 Shares Outstanding (Millions) 145
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -243
 Cash Flow (TTM) (Millions $) 197
 Capital Exp. (TTM) (Millions $) 0

Immunovant Inc
Immunovant Inc is a biopharmaceutical company that focuses on developing novel therapies for autoimmune diseases. The company utilizes a proprietary technology platform to develop small molecules and monoclonal antibodies that target specific components of the immune system to modulate immune responses.

Immunovant's lead candidate, IMVT-1401, is an investigational anti-FcRn antibody being developed for the treatment of autoimmune diseases, including myasthenia gravis and pemphigus vulgaris. FcRn is a protein that plays a role in the recycling of immunoglobulins, and by inhibiting its function, IMVT-1401 aims to reduce the levels of pathogenic antibodies that contribute to autoimmune disease.

The company's research and development efforts are driven by a team of experienced scientists and clinicians with expertise in immunology and autoimmune diseases. Immunovant is committed to advancing its pipeline of innovative therapies to address the unmet medical needs of patients with autoimmune disorders.

Immunovant Inc was previously a subsidiary of Roivant Sciences but became an independent publicly traded company in October 2019. The company is headquartered in New York, United States.


   Company Address: 320 West 37th Street New York, 10018 NY
   Company Phone Number: 580-3099   Stock Exchange / Ticker: NASDAQ IMVT
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Immunovant Inc

Immunovant Inc Shows Promising Financial Performance in Q4 2023

Immunovant Inc, a clinical-stage immunology company focused on autoimmune diseases, has reported improved financial results for the three months ending December 31, 2023. The company's loss per share decreased to $-0.36 per share, compared to $-0.49 per share in the same period the previous year. This represents an improvement in earnings compared to the preceding financial reporting period, where the company realized $-0.45 per share.
During the October to December 2023 timeframe, Immunovant Inc reported a net loss of $-51.418 million, which is a reduction from the $-63.227 million loss in the comparable financial reporting period a year ago. This indicates a positive trend in the company's financial performance.

Clinical Study

Immunovant's Batoclimab Demonstrates Remarkable Efficacy in Phase 2 Trial for Graves Disease

Published Wed, Dec 20 2023 9:30 PM UTC

NEW YORK, Dec. 20, 2023 - Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company committed to enhancing the quality of life for individuals with autoimmune diseases, has made a groundbreaking breakthrough with its drug, batoclimab. The initial data from a 24-week Phase 2 clinical trial has unveiled extraordinary results, showcasing response rates surpassing 50%...

Clinical Study

Immunovant's IMVT-1402 Sets New Standard in Autoimmune Disease Treatment as a Best-in-Class FcRn Inhibitor

Published Tue, Nov 28 2023 12:00 PM UTC

Immunovant's IMVT-1402 Demonstrates Promising Results as a Best-in-Class FcRn Inhibitor
NEW YORK, Nov. 28, 2023 - Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company committed to improving the lives of individuals with autoimmune diseases, has announced positive early findings from the Phase 1 clinical trial of IMVT-1402. These initial results from the 6...

Immunovant Inc

Company Records Soaring Losses in Financial Year 2023, Exceeding Previous Year's Figures

Immunovant Inc, a clinical-stage immunology company focusing on autoimmune diseases, has experienced a decrease in diminishing returns in the fiscal interval closing September 30, 2023. The company witnessed a decrease in returns of $-0.45 per share compared to $-0.41 per share in the previous year's financial reporting period. However, this is still an improvement from the $-0.57 per share realized in the preceding financial reporting period.
In terms of net shortfall, Immunovant Inc reported a total of $-58.662 million in the fiscal interval closing September 30, 2023. This is higher than the $-47.928 million reported a year ago. Despite this increase in net shortfall, the company has made progress in terms of accounts receivable, although it still remains below the level of the previous year.

Immunovant Inc

Immunovant Inc Faces Rising Business Costs, Posts Significant Operating Deficit in Q1 of FY 2023

Biotechnology & Pharmaceuticals sector advisors are closely examining the first quarter earnings of Immunovant Inc, a company specializing in immunotherapy treatments. According to the advisors, the company reported an operating deficit of $-78.477 million for the financial reporting period of April to June 30, 2023. This represents a significant decline from the previous year's first quarter operating deficit of $-40.375 million.
Of particular concern to analysts is the lack of revenue reported by Immunovant Inc. The company has yet to generate any revenue, leaving investors wondering when they will start seeing positive returns from their investments. Despite this, the organization's net deficit stands at $-73.937 million, a noticeable increase from the previous year's deficit of $-40.373 million during the same period.






 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com